Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • This study assessed the efficacy and safety of switching virologically suppressed patients from a regimen of dolutegravir plus abacavir/lamivudine (either as separate components or as a coformulated regimen) to bictegravir/emtricitabine/tenofovir AF
    • At Week 48, switching to the bictegravir regimen met the criteria for noninferiority with continuation of the dolutegravir-based regimen
    • Adverse events occurred in similar proportions in each group

Action required